Invention Grant
![1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors](/docs/US/2017-07-18/US09708315B2/abs.jpg.600x600.jpg)
- Patent Title: 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
-
Application No.: US14916703Application Date: 2014-09-03
-
Publication No.: US09708315B2Publication Date: 2017-07-18
- Inventor: José Maria Cid-Núñez , Andrés Avelino Trabanco-Suárez , Marc André Ceusters , Hilde Lavreysen
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Priority: EP13183427 20130906; EP14153887 20140204
- International Application: PCT/EP2014/068676 WO 20140903
- International Announcement: WO2015/032790 WO 20150312
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/198 ; A61K31/437
![1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors](/abs-image/US/2017/07/18/US09708315B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.
Public/Granted literature
Information query
